Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.
Humans
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Antibodies, Monoclonal, Humanized
/ administration & dosage
Male
Female
Middle Aged
Lung Neoplasms
/ drug therapy
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Double-Blind Method
B7-H1 Antigen
/ antagonists & inhibitors
Sulfonamides
/ administration & dosage
Adult
Oximes
/ administration & dosage
Aged, 80 and over
Progression-Free Survival
Combination immunotherapy
Epacadostat
Non-small cell lung cancer
PD-L1 high
Pembrolizumab
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
received:
19
08
2022
accepted:
19
07
2023
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab with other immunotherapies may enhance tumor cell killing and clinical outcomes. Epacadostat is a selective inhibitor of indoleamine 2,3-dioxygenase 1, an immuno-regulatory enzyme involved in tryptophan to kynurenine metabolism that inhibits T cell-mediated immune responses. In this randomized phase II study, patients with metastatic NSCLC expressing high (≥ 50%) programmed death-ligand 1 (PD-L1) levels received pembrolizumab 200 mg every 21 days plus oral epacadostat 100 mg twice daily (combination) or matching placebo (control). The primary objective was objective response rate (ORR); secondary objectives were progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety/tolerability. 154 patients were randomized (77 per group). Median (range) follow-up was 6.8 months (0.1-11.4) and 7.0 months (0.2-11.9) in the combination and control groups, respectively Confirmed ORR was similar between groups (combination: 32.5%, 95% CI 22.2-44.1; control: 39.0%, 95% CI 28.0-50.8; difference: - 6.5, 95% CI - 21.5 to 8.7; 1-sided P = 0.8000). Median (range) DOR was 6.2 months (1.9 + to 6.5 +) and not reached (1.9 + to 8.6 +) in the combination and control groups, respectively. Although not formally tested, median PFS was 6.7 and 6.2 months for the combination and control groups, respectively, and median OS was not reached in either group. Circulating kynurenine levels increased from C1D1 to C2D1 (P < 0.01) in the control group and decreased from C1D1 to C2D1 (P < 0.01) in the combination group but were not normalized in most patients. The most frequent serious adverse events (AEs) (≥ 2%) were pneumonia (4.0%), anemia (2.7%), atelectasis (2.7%) and pneumonitis (2.7%) in the combination group and pneumonia (3.9%), pneumonitis (2.6%) and hypotension (2.6%) in the control group. Two deaths due to drug-related AEs were reported, both in the control group. Addition of epacadostat to pembrolizumab therapy for PD-L1-high metastatic NSCLC was generally well tolerated but did not demonstrate an improved therapeutic effect. Evaluating higher doses of epacadostat that normalize kynurenine levels when given in combination with checkpoint inhibitors may be warranted. ClinicalTrials.gov, NCT03322540. Registered 10/26/2017.
Sections du résumé
BACKGROUND
BACKGROUND
Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab with other immunotherapies may enhance tumor cell killing and clinical outcomes. Epacadostat is a selective inhibitor of indoleamine 2,3-dioxygenase 1, an immuno-regulatory enzyme involved in tryptophan to kynurenine metabolism that inhibits T cell-mediated immune responses.
METHODS
METHODS
In this randomized phase II study, patients with metastatic NSCLC expressing high (≥ 50%) programmed death-ligand 1 (PD-L1) levels received pembrolizumab 200 mg every 21 days plus oral epacadostat 100 mg twice daily (combination) or matching placebo (control). The primary objective was objective response rate (ORR); secondary objectives were progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety/tolerability.
RESULTS
RESULTS
154 patients were randomized (77 per group). Median (range) follow-up was 6.8 months (0.1-11.4) and 7.0 months (0.2-11.9) in the combination and control groups, respectively Confirmed ORR was similar between groups (combination: 32.5%, 95% CI 22.2-44.1; control: 39.0%, 95% CI 28.0-50.8; difference: - 6.5, 95% CI - 21.5 to 8.7; 1-sided P = 0.8000). Median (range) DOR was 6.2 months (1.9 + to 6.5 +) and not reached (1.9 + to 8.6 +) in the combination and control groups, respectively. Although not formally tested, median PFS was 6.7 and 6.2 months for the combination and control groups, respectively, and median OS was not reached in either group. Circulating kynurenine levels increased from C1D1 to C2D1 (P < 0.01) in the control group and decreased from C1D1 to C2D1 (P < 0.01) in the combination group but were not normalized in most patients. The most frequent serious adverse events (AEs) (≥ 2%) were pneumonia (4.0%), anemia (2.7%), atelectasis (2.7%) and pneumonitis (2.7%) in the combination group and pneumonia (3.9%), pneumonitis (2.6%) and hypotension (2.6%) in the control group. Two deaths due to drug-related AEs were reported, both in the control group.
CONCLUSIONS
CONCLUSIONS
Addition of epacadostat to pembrolizumab therapy for PD-L1-high metastatic NSCLC was generally well tolerated but did not demonstrate an improved therapeutic effect. Evaluating higher doses of epacadostat that normalize kynurenine levels when given in combination with checkpoint inhibitors may be warranted.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov, NCT03322540. Registered 10/26/2017.
Identifiants
pubmed: 39054476
doi: 10.1186/s12885-023-11203-8
pii: 10.1186/s12885-023-11203-8
doi:
Substances chimiques
pembrolizumab
DPT0O3T46P
Antibodies, Monoclonal, Humanized
0
epacadostat
71596A9R13
B7-H1 Antigen
0
Sulfonamides
0
CD274 protein, human
0
Oximes
0
Banques de données
ClinicalTrials.gov
['NCT03322540']
Types de publication
Journal Article
Clinical Trial, Phase II
Randomized Controlled Trial
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1251Informations de copyright
© 2023. The Author(s).
Références
American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2019.
Besse B, Adjei A, Baas P, Melgaard P, Nicolson M, Paz-Ars L, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475–84.
doi: 10.1093/annonc/mdu123
pubmed: 24669016
Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. J Immunother Cancer. 2022;10(5):e003956.
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Update published 18 Sep 2019. https://www.esmo.org/content/download/227453/3874538/file/ESMO-CPG-mNSCLC-18SEPT2019.pdf . Accessed 18 Aug 2020.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
doi: 10.1056/NEJMoa1606774
pubmed: 27718847
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46.
doi: 10.1200/JCO.18.00149
pubmed: 30620668
Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35(Suppl):S185–98.
doi: 10.1016/j.semcancer.2015.03.004
pubmed: 25818339
Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762–74.
doi: 10.1038/nri1457
pubmed: 15459668
Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176(11):6752–61.
doi: 10.4049/jimmunol.176.11.6752
pubmed: 16709834
Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269–74.
doi: 10.1038/nm934
pubmed: 14502282
Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, et al. Differential expression and significance of PD-L1, IDO-1, and B7–H4 in human lung cancer. Clin Cancer Res. 2017;23(2):370–8.
doi: 10.1158/1078-0432.CCR-16-0150
pubmed: 27440266
Takada K, Kohashi K, Shimokawa M, Haro A, Osoegawa A, Tagawa T, et al. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: potential targets of novel combination therapy. Lung Cancer. 2019;128:26–32.
doi: 10.1016/j.lungcan.2018.12.008
pubmed: 30642449
Volaric A, Gentzler R, Hall R, Mehaffey JH, Stelow EB, Bullock TN, et al. Indoleamine-2,3-dioxygenase in non-small cell lung cancer: a targetable mechanism of immune resistance frequently coexpressed with PD-L1. Am J Surg Pathol. 2018;42(9):1216–23.
doi: 10.1097/PAS.0000000000001099
pubmed: 29901571
Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, et al. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J Transl Med. 2018;16(1):219.
doi: 10.1186/s12967-018-1595-3
pubmed: 30081936
pmcid: 6080500
Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210(7):1389–402.
doi: 10.1084/jem.20130066
pubmed: 23752227
pmcid: 3698523
Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5(11):2516–22.
doi: 10.1096/fasebj.5.11.1907934
pubmed: 1907934
Toulmonde M, Penel N, Adam J, Chevreau C, Blay J-Y, Le Cesne A, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):93–7.
doi: 10.1001/jamaoncol.2017.1617
pubmed: 28662235
Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115(17):3520–30.
doi: 10.1182/blood-2009-09-246124
pubmed: 20197554
Beatty GL, O’Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, et al. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res. 2017;23(13):3269–76.
doi: 10.1158/1078-0432.CCR-16-2272
pubmed: 28053021
pmcid: 5496788
Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, et al. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018;36(32):3223–30.
doi: 10.1200/JCO.2018.78.9602
pubmed: 30265610
pmcid: 6225502
ClinicalTrials.gov. Study to explore the safety, tolerability and efficacy of MK-3475 in combination with INCB024360 in participants with selected cancers. Identifier NCT02178722. https://clinicaltrials.gov/ct2/show/results/NCT02178722 . Accessed 18 Aug 2020.
Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083–97.
doi: 10.1016/S1470-2045(19)30274-8
pubmed: 31221619
Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213–26.
doi: 10.1002/sim.4780040211
pubmed: 4023479
Boyer M, Hui R, Urban D, Clingan P, Su W-C, Devaux C, et al. Epacadostat plus pembrolizumab with platinum-based chemotherapy versus placebo plus pembrolizumab with platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: a randomized, double-blind, phase II study. BMC Cancer. This issue.
Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847.
doi: 10.3389/fimmu.2018.00847
pubmed: 29780381
pmcid: 5945880
Çiçin I, Plimack ER, Gurney H, Leibowitz-Amit R, Alekseev BY, Parnis FX, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the ECHO-303/KEYNOTE-698 study. BMC Cancer. This issue.
Smith M, Newton R, Owens S, Gong X, Tian C, Malesk J, Leopold L. Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies. J Immunother Cancer. 2020; 8(Suppl 3): Abstract 28. https://doi.org/10.1136/jitc-2020-SITC2020.0028 .
Yao Y, Liang H, Fang X, Zhang S, Xing Z, Shi L, Kuang C, Seliger B, Yang Q. What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past. J Exp Clin Cancer Res. 2021;40(1):60.
doi: 10.1186/s13046-021-01847-4
pubmed: 33557876
pmcid: 7869231
Perez RP, Reis MJ, Lewis KD, Saleh MN, Daud A, Berlin J, et al. Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204. J Clin Oncol. 2017;35(suppl 15):3003.
doi: 10.1200/JCO.2017.35.15_suppl.3003
Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, et al. Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors. Clin Cancer Res. 2019;25(11):3220–8.
doi: 10.1158/1078-0432.CCR-18-2740
pubmed: 30770348
pmcid: 7980952